Clinical Trial

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-26.
Status change: Not Yet Recruiting → Recruiting 2025-03-19
Trial Details
NCT Number NCT06854445
Lead Sponsor Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions Diffuse Large Cell B-lymphoma
Enrollment 55 participants
Start Date 2025-03-12
Primary Completion 2025-10 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2025-03-24